Table 1 CAB risk stratification across patient demographics and clinicopathological parameters.
From: Real-world data of CanAssist Breast- first immunohistochemistry and AI-based prognostic test
Parameters | Subgroups | Total no. of patients n (%) | CAB low risk n (%) | CAB high risk n (%) |
|---|---|---|---|---|
Total | 5926 | 4290 (72) | 1636 (28) | |
Age (Years) | ≤ 48 | 1320 (22) | 998 (76) | 322 (24) |
> 48 | 4606 (78) | 3292 (71) | 1314 (29) | |
Range | 24–91 | |||
Median in ≤ 48 | 43 | |||
Median in > 48 | 61 | |||
Overall Median | 58 | |||
Gender | Female | 5877 (99) | 4255 (72) | 1622 (28) |
Male | 49 (1) | 35 (71) | 14 (29) | |
Tumor size | T1 | 2022 (34) | 1679 (83) | 343 (17) |
T2 | 3794 (64) | 2610 (69) | 1184 (31) | |
T3 | 110 (2) | 1 (1) | 109 (99) | |
Node status | N0 | 4861 (82) | 3818 (79) | 1043 (21) |
N1 | 1065 (18) | 472 (44) | 593 (56) | |
Histological tumor grade | G1 | 920 (16) | 870 (95) | 50 (5) |
G2 | 3832 (65) | 3123 (81) | 709 (19) | |
G3 | 1174 (20) | 297 (25) | 877 (75) | |
Hormone receptor status | ER +/PR + | 5424 (92) | 3953 (73) | 1471 (27) |
ER +/PR- | 435 (7) | 299 (69) | 136 (31) | |
ER-/PR + | 15 (0) | 8 (53) | 7 (47) | |
